BI’s Pradaxa Gets Mixed Reviews In Postmarketing Studies
Executive Summary
Two observational studies of Medicare patients reach different conclusions on Pradaxa bleeding rates, but FDA says risk/benefit profile of drug has not changed.
You may also be interested in...
Boehringer/WellPoint Outcomes Research To Inform Pradaxa Treatment
The study in non-valvular atrial fibrillation patients is the first project to launch under a five-year research agreement between Boehringer Ingelheim and WellPoint.
Pradaxa Medicare Study: Observing a Slow Attitude Change at FDA on Observational Studies
CDER Deputy Director Bob Temple is a confirmed skeptic of the value of observational trial data to FDA’s regulatory decisions. A recent Medicare study on the bleeding risks associated with Boehringer-Ingelheim’s Pradaxa, however, confirmed an earlier position on the drug by FDA and meets with Temple’s approbation.
FDA Finds “Comfort Level” With Using Medicare Data For Sentinel Initiative
FDA research into the clinical accuracy and stability over time of Medicare claims data has shown it could be a reliable source of information for active product safety surveillance, according to FDA’s Judy Racoosin, scientific lead for the Sentinel Initiative within the Center for Drug Evaluation and Research.